1. Cancers (Basel). 2020 Dec 14;12(12):3758. doi: 10.3390/cancers12123758.

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted 
Non-Small Cell Lung Cancer.

Geraud A(1)(2), Mezquita L(1)(3), Auclin E(4), Combarel D(5)(6), Delahousse 
J(5), Gougis P(7)(8), Massard C(2)(9), Jovelet C(10), Caramella C(11), Adam 
J(12), Naltet C(1), Lavaud P(1), Gazzah A(2), Lacroix L(10), Rouleau E(10), 
Vasseur D(10), Mir O(13), Planchard D(1), Paci A(5)(6), Besse B(1)(9).

Author information:
(1)Cancer Medicine Department, Gustave Roussy, 94805 Villejuif, France.
(2)Early Drug Development Department (DITEP), Gustave Roussy, 94805 Villejuif, 
France.
(3)Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i 
Sunyer Biomedical Research Institute (IDIBAPS), Medical Oncology Department, 
Hospital Clínic, 08036 Barcelona, Spain.
(4)Department of Medical and Digestive Oncology, Hôpital Européen Georges 
Pompidou, Assistance Publique des Hôpitaux de Paris, 75015 Paris, France.
(5)Pharmacology Department, Gustave Roussy, 94805 Villejuif, France.
(6)Faculty of Pharmacy, Paris-Saclay University, 92296 Chatenay-Malabry, France.
(7)Department of Pharmacology and Clinical Investigation Center, 
Pitié-Salpêtrière Hospital, INSERM, CIC-1421, Sorbonne University, 75013 Paris, 
France.
(8)CLIP2 Galilée, Regional Pharmacovigilance Center, Pitié-Salpêtrière Hospital, 
INSERM, CIC-1421, Sorbonne University, 75013 Paris, France.
(9)Paris-Saclay University, Cancer Campus Gustave Roussy, Gustave Roussy, 94805 
Villejuif, France.
(10)Department of Medical Biology and Pathology, Gustave Roussy, 94805 
Villejuif, France.
(11)Department of Medical Imaging, Gustave Roussy, 94805 Villejuif, France.
(12)Pathology Department, Gustave Roussy, 94805 Villejuif, France.
(13)Department of Ambulatory Cancer Care, Gustave Roussy, 94805 Villejuif, 
France.

Kinase inhibitors (KI) have dramatically improved the outcome of treatment in 
patients with non-small cell lung cancer (NSCLC), which harbors an oncogene 
addiction. This study assesses KI plasma levels and their clinical relevance in 
patients chronically exposed to KIs. Plasma samples were collected in NSCLC 
patients receiving erlotinib, gefitinib, osimertinib, crizotinib, or dabrafenib 
(with or without trametinib) for at least three months between November 2013 and 
February 2019 in a single institution. KI drug concentrations were measured by 
ultra-performance liquid chromatography coupled with tandem mass spectrometry 
and compared to published data defining optimal plasma concentration. The main 
outcome was the rate of samples with suboptimal KI plasma concentrations. 
Secondary outcomes included its impact on T790M mutation emergence in patients 
receiving a first-generation epidermal growth factor receptor (EGFR) KI. 
Fifty-one samples were available from 41 patients with advanced NSCLC harboring 
driver genetic alterations, including EGFR, v-Raf murine sarcoma viral oncogene 
homolog B (BRAF), anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 
(ROS1), and who had an available evaluation of chronic KI plasma exposure. 
Suboptimal plasma concentrations were observed in 51% (26/51) of cases. In 
EGFR-mutant cases failing first-generation KIs, EGFR exon 20 p.T790M mutation 
emergence was detected in 31% (4/13) of samples in optimal vs. none in 
suboptimal concentration (0/5). Suboptimal plasma concentrations of KIs are 
frequent in advanced NSCLC patients treated with a KI for at least three months 
and might contribute to treatment failure.

DOI: 10.3390/cancers12123758
PMCID: PMC7764991
PMID: 33327482

Conflict of interest statement: Arthur Geraud: As part of the Drug Development 
Department (DITEP) Principal/sub-Investigator of Clinical Trials for Abbvie, 
Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno 
Therapeutics, Astex Pharmaceuticals, Astra Zeneca, Astra Zeneca Ab, Aveo, Bayer 
Healthcare Ag, Bbb Technologies Bv, Beigene, Bioalliance Pharma, Biontech Ag, 
Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers 
Squibb, Bristol-Myers Squibb International Corporation, Ca, Celgene Corporation, 
Cephalon, Chugai Pharmaceutical Co., Clovis Oncology, Cullinan-Apollo, Daiichi 
Sankyo, Debiopharm S.A., Eisai, Eisai Limited, Eli Lilly, Exelixis, Forma 
Tharapeutics, Gamamabs, Genentech, Gilead Sciences, Glaxosmithkline, Glenmark 
Pharmaceuticals, H3 Biomedicine, Hoffmann La Roche Ag, Incyte Corporation, 
Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Janssen Cilag, 
Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev., Lilly 
France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck 
Kgaa, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium 
Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, 
Nerviano Medical Sciences, Novartis Pharma, Octimet Oncology Nv, Oncoethix, 
Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Ose 
Pharma, Pfizer, Pharma Mar, Philogen S.P.A., Pierre Fabre Medicament, Plexxikon, 
Rigontec Gmbh, Roche, Sanofi Aventis, Sierra Oncology, Sotio A.S, Syros 
Pharmaceuticals, Taiho Pharma, Tesaro, Tioma Therapeutics, Wyeth Pharmaceuticals 
France, Xencor, Y’s Therapeutics, Research Grants from Astrazeneca, BMS, 
Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi. 
Non-financial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher 
Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, 
Roche. Laura Mezquita: Sponsored Research: Bristol-Myers Squibb, Boehringer 
Ingelheim, Amgen. Consulting, advisory role: Roche Diagnostics, Roche, Takeda. 
Lectures and educational activities: Bristol-Myers Squibb, Tecnofarma, Roche. 
Travel, Accommodations, Expenses: Bristol-Myers Squibb, Roche. Mentorship 
program with key opinion leaders: funded by AstraZeneca. Edouard Auclin: Travel 
expenses: Mundipharma. Lectures and educational activities: Sanofi Genzymes. 
David Combarel: Nothing to disclose. Julia Delahousse: Nothing to disclose. Paul 
Gougis: Nothing to disclose. Christophe Massard: Consultant/Advisory fees: 
Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, 
Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, 
Sanofi, Orion. Principal/sub-Investigator of ClinicalTrials: Abbvie, Aduro, 
Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveopharmaceuticals, Bayer, Beigene, 
Blueprint, BMS, BoeringerIngelheim, Celgene, Chugai, Clovis, DaiichiSankyo, 
Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 
biomedecine, Incyte, InnatePharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, 
Lysarc, LytixBiopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, 
NektarTherapeutics, Novartis, Octimet, Oncoethix, OncopeptidesAB, Orion, Pfizer, 
Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, 
Tesaro, Xencor. Cécile Jovelet: Nothing to disclose. Caroline Caramella: 
Honorarium: Pfizer, BMS, MSK, Astra Zeneca. Julien Adam: Advisor/consultant for: 
AstraZeneca, Bayer, BMS, MSD, Roche. Charles Naltet: Travel expenses: Pfizer, 
Roche, AstraZeneca. Pernelle Lavaud: Travel, accommodation, congress 
registration expenses: Astra Zeneca, Mundi Pharma, Ipsen, Astellas, Janssen. 
Anas Gazzah: Travel, accommodation, congress registration expenses from 
Boehringer Ingelheim, Novartis, Pfizer, Roche. Consultant/Expert role for 
Novartis. Principal/sub-Investigator of Clinical Trials for Aduro Biotech, Agios 
Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, 
Astra Zeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, 
Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, 
Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co., Clovis 
Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Exelixis, Forma, Gamamabs, 
Genentech, Inc., Gilead Sciences, Inc, Glaxosmithkline, Glenmark 
Pharmaceuticals, H3 Biomedicine, Inc, Hoffmann La Roche Ag, Incyte Corporation, 
Innate Pharma, Iris Servier, Janssen, Kura Oncology, Kyowa Kirin Pharm, Lilly, 
Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & 
Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, 
Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, 
Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon 
Genomics, Pfizer, Pharma Mar, Pierre Fabre, Rigontec Gmbh, Roche, Sanofi 
Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Inc, Tioma Therapeutics, Inc., 
Xencor. Research Grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen 
Cilag, Merck, Novartis, Pfizer, Roche, Sanofi. Non-financial support (drug 
supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, 
Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. Ludovic Lacroix: 
Consultancy: Abbott, Astrazeneca, Boehringer Ingelheim, Bristol Myers Squibb, Ca 
Bayer Healthcarer, Illumina, Genomic Health, Myriad, Novartis, Pfizer, Roche, 
Siemens, Thermofisher, VelaDx. Etienne Rouleau: Board participations: MS, 
AstraZeneca, Roche. Damien Vasseur: Nothing to disclose. Olivier Mir: 
Consultancy: Amgen, Astra-Zeneca, Bayer, Bristol Myers-Squibb, Eli-Lilly, Ipsen, 
Lundbeck, MSD, Novartis, Pfizer, Roche, Servier, Vifor Pharma. Speakers bureau: 
Eli-Lilly, Roche, Servier. Stock ownership: Amplitude surgical, Ipsen, 
Transgene. David Planchard: Consulting, advisory role or lectures: AstraZeneca, 
Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, 
Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche. Honoraria: 
AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, 
Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche. Clinical trials 
research: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, 
Merck, Novartis, Pfizer, Roche, Medimmune, Sanofi-Aventis, Taiho Pharma, 
Novocure, Daiichi Sankyo. Travel, Accommodations, Expenses: AstraZeneca, Roche, 
Novartis, prIME Oncology, Pfizer. Angelo Paci: Consulting, advisory role or 
lectures: Fresenius, Pierre Fabre, Pfizer, Servier. Travel, Accommodations, 
Expenses: Fresenius, Pierre Fabre. Benjamin Besse: Grant Abbvie, Amgen, 
AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, 
IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum 
Pharmaceuticals, Takeda, Tiziana Pharma, Investigator or co-investigator of 
trials: Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, 
Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma 
Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma. This research did 
not receive any specific grant from funding agencies in the public, commercial, 
or not-for-profit sectors.